Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study

References

• Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996;334:13-18
   PubMed Web of Science ®Google Scholar
• Pinto-Sietsma S-J, Navis G, Janssen WMT, et al. A central body fat distribution is related to renal function impairment, even in lean subjects. Am J Kidney Dis 2003;41:733-41
   PubMed Web of Science ®Google Scholar
• Beddhu S, Kimmel PL, Ramkumar N, et al. Associations of metabolic syndrome with inflammation in CKD: results from the third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2005;46:577-86
   PubMed Web of Science ®Google Scholar
• Crook ED, Thallapureddy A, Migdal S, et al. Lipid abnormalities and renal disease: is dyslipidemia a predictor of progression of renal disease? Am J Med Sci 2003;325:340-8
   PubMed Web of Science ®Google Scholar
• Straznicky NE, Grima MT, Lambert EA, et al. Exercise augments weight loss induced improvement in renal function in obese metabolic syndrome individuals. J Hypertens 2011;29:553-64
   PubMed Web of Science ®Google Scholar
• Ninomiya T, Kiyohara Y, Kubo M, et al. Metabolic syndrome and CKD in a general Japanese population: the Hisayama Study. Am J Kidney Dis 2006;48:383-91
   PubMed Web of Science ®Google Scholar
• Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. Ann Intern Med 2004;140:167-74
   PubMed Web of Science ®Google Scholar
• Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 2005;16:2134-40
   PubMed Web of Science ®Google Scholar
• Nitta K. Possible link between metabolic syndrome and chronic kidney disease in the development of cardiovascular disease. Cardiol Res Pract 2011;2011:963517
   Google Scholar
• Tuttle KR. Renal manifestations of the metabolic syndrome. Nephrol Dial Transplant 2005;20:861-4
   PubMed Web of Science ®Google Scholar
• Tsouli SG, Liberopoulos EN, Mikhailidis DP, et al. Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism 2006;55:1293-301
   PubMed Web of Science ®Google Scholar
• Kang DH, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002;13:2888-97
   PubMed Web of Science ®Google Scholar
• Bickel C, Rupprecht HJ, Blankenberg S, et al. Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 2002;89:12-17
   PubMed Web of Science ®Google Scholar
• Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971–1992. National Health and Nutrition Examination Survey. JAMA 2000;283:2404-10
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Daniels SR, et al; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52
   PubMed Web of Science ®Google Scholar
• Chimonas T, Karagiannis A, Athyros VG, et al. Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible diabeTes (ATTEMPT) Collaborative Group. Blood pressure levels constitute the most important determinant of the metabolic syndrome in a Mediterranean population: a discrimination analysis. Metab Syndr Relat Disord 2010;8:523-9
   PubMedGoogle Scholar
• Chimonas T, Athyros VG, Ganotakis E, Chimonas T, Karagiannis A, Athyros VG.; Assessing the Treatment Effect in Metabolic Syndrome Without Perceptible diabeTes (ATTEMPT) Collaborative Group. Cardiovascular risk factors and estimated 10-year risk of fatal cardiovascular events using various equations in Greeks with metabolic syndrome. Angiology 2010;61:49-57
   PubMed Web of Science ®Google Scholar
• Athyros VG, Ganotakis E, Kolovou G, et al.; for the Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible diabeTes (ATTEMPT) Collaborative Group. Assessing The Treatment Effect in Metabolic syndrome without Perceptible diabeTes (ATTEMPT). A prospective-randomized study in middle aged men and women. Curr Vasc Pharmacol 2011; in press
   Google Scholar
• Shaw JS, Wilmot RL, Kilpatrick ES. Establishing pragmatic estimated GFR thresholds to guide metformin prescribing. Diabet Med 2007;24:1160-3
   PubMed Web of Science ®Google Scholar
• Salpeter S, Greyber E, Pasternak G, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2006;25:CD002967
   Google Scholar
• Athyros VG, Karagiannis A, Hatzitolios AI, et al. SAGE-METS collaborative group. Standardized arrangement for a guideline-driven treatment of the metabolic syndrome: the SAGE-METS study. Curr Med Res Opin 2009;25:971-80
   PubMed Web of Science ®Google Scholar
• Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985;33:278-85
   PubMed Web of Science ®Google Scholar
• Leoncini G, Viazzi F, Pontremoli R. Chronic kidney disease and albuminuria in arterial hypertension. Curr Hypertens Rep 2010;12:335-41
   PubMed Web of Science ®Google Scholar
• Dalrymple LS, Kaysen GA. The effect of lipoproteins on the development and progression of renal disease. Am J Nephrol 2008;28:723-31
   PubMed Web of Science ®Google Scholar
• Brancati FL, Whelton PK, Randall BL, et al. Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial. JAMA 1997;278:2069-74
   PubMed Web of Science ®Google Scholar
• de Jong PE, Verhave JC, Pinto-Sietsma SJ, et al. Obesity and target organ damage: the kidney. Int J Obes Relat Metab Disord 2002;26(Suppl 4):S21-4
   PubMed Web of Science ®Google Scholar
• Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154-69
   PubMed Web of Science ®Google Scholar
• Navaneethan SD, Pansini F, Perkovic V, et al. HMGCoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.: CD007784. DOI: 10.1002/14651858.CD007784
   Google Scholar
• US Renal Data System. USRDS 2006 Annual data report, part 2: incidence and prevalence. Available at: www.usrds.org/adr_2006.htm. Accessed April 14, 2011
   Google Scholar
• Sandhu S, Wiebe N, Fried LF, et al. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 2006;17:2006-16
   PubMed Web of Science ®Google Scholar
• Tonelli M, Isles C, Craven T, et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 2005;112:171-8
   PubMed Web of Science ®Google Scholar
• Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16
   PubMed Web of Science ®Google Scholar
• Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidemia on renal function in patients with coronary heart disease: a subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004;57:728-34
   PubMed Web of Science ®Google Scholar
• Athyros VG, Mikhailidis DP, Liberopoulos EN, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 2007;22:118-27
   PubMed Web of Science ®Google Scholar
• Athyros VG, Mitsiou EK, Tziomalos K, et al. Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy. Expert Opin Pharmacother 2010;11:723-30
   PubMed Web of Science ®Google Scholar
• Athyros VG, Karagiannis A, Kakafika A, et al. Statins and renal function. Is the compound and dose making a difference? Nephrol Dial Transplant 2007;22:963-4
   PubMed Web of Science ®Google Scholar
• Shepherd J, Kastelein JJ, Bittner V, et al. Treating to New Targets Investigators. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol 2007;2:1131-9
   PubMed Web of Science ®Google Scholar
• Shepherd J, Kastelein JJ, Bittner V, et al. TNT (Treating to New Targets) Investigators. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol 2008;51:1448-54
   PubMed Web of Science ®Google Scholar
• Colhoun HM Betteridge DJ, Durrington PN, et al., and CARDS Investigators. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis 2009;54:810-19
   PubMed Web of Science ®Google Scholar
• Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J 2010;160:785-94
   PubMed Web of Science ®Google Scholar
• Navaneethan SD, Hegbrant J, Strippoli GF. Role of statins in preventing adverse cardiovascular outcomes in patients with chronic kidney disease. Curr Opin Nephrol Hypertens 2011;20:146-52
   PubMed Web of Science ®Google Scholar
• Fellström B, Holdaas H, Jardine AG, et al; AURORA Study Group. Cardiovascular disease in patients with renal disease: the role of statins. Curr Med Res Opin 2009;25:271-85
   PubMed Web of Science ®Google Scholar
• Palmer BF, Fenves AZ. Optimizing blood pressure control in patients with chronic kidney disease. Proc (Bayl Univ Med Cent) 2010;23:239-45
   PubMedGoogle Scholar
• Jafar TH, Stark PC, Schmid CH, et al. for the AIPRD Study Group: Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition. A patient-level meta-analysis. Ann Intern Med 2003;139:244-52
   PubMed Web of Science ®Google Scholar
• Griffin KA, Bidani AK. Progression of renal disease: renoprotective specificity of renin-angiotensin system blockade. Clin J Am Soc Nephrol 2006;1:1054-65
   PubMed Web of Science ®Google Scholar
• Athyros VG, Mikhailidis DP, Papageorgiou AA, et al; GREACE Study Collaborative Group. Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. J Hum Hypertens 2004;18:781-8
   PubMed Web of Science ®Google Scholar
• Bakris GL, Sarafidis PA, Weir MR, et al; ACCOMPLISH Trial investigators. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010;375:1173-81
   PubMed Web of Science ®Google Scholar
• Jamerson K, Weber MA, Bakris GL, et al. ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417-28
   PubMed Web of Science ®Google Scholar
• Ioachimescu AG, Brennan DM, Hoar BM, et al. Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study. Arthritis Rheum 2008;58:623-30
   PubMed Web of Science ®Google Scholar
• Athyros VG, Elisaf M, Papageorgiou AA, et al; GREACE Study Collaborative Group. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis 2004;43:589-99
   PubMed Web of Science ®Google Scholar
• Daskalopoulou SS, Mikhailidis DP, Athyros VG, et al. Fenofibrate and losartan. Ann Rheum Dis 2004;63:469-70
   PubMed Web of Science ®Google Scholar
• Karagiannis A, Mikhailidis DP, Athyros VG, et al. The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal? Expert Opin Ther Targets 2007;11:191-205
   PubMed Web of Science ®Google Scholar
• Hoieggen A, Alderman MH, Kjeldsen SE, et al. LIFE Study Group. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004;65:1041-9
   PubMed Web of Science ®Google Scholar
• Daskalopoulou SS, Athyros VG, Elisaf M, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004;66:1714-15
   PubMed Web of Science ®Google Scholar
• Katsiki N, Athyros VG, Karagiannis A, et al. Hyperuricaemia and Non-Alcoholic Fatty Liver Disease (NAFLD): A relationship with implications for vascular risk? Curr Vasc Pharmacol 2011 Mar 10. [Epub ahead of print]
   Google Scholar
• National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl 1):S1-266
   PubMed Web of Science ®Google Scholar